Black checkmark with a sparkle and a curved line underneath on a white background.
Company

MYOMO, INC.

Ticker
MYO
Sector
Industry
Report date
November 11, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

MYOMO reported record third quarter 2026 revenue of $12.3 million alongside a net loss for the quarter. The company continues to show revenue growth despite operating losses, supported by a solid liquidity position as of September 30, 2026.

Recent developments:
  • MYOMO reported record third quarter 2026 revenue of $12.3 million [N1].
  • The company reported a net loss of $4.23 million for Q3 2026 with EPS of -$0.10 per share [N3][S2].
  • Cash and cash equivalents totaled approximately $11.1 million as of September 30, 2026, with a current ratio of 1.92 and a cash ratio of 0.97 [S2].
  • The Q3 2026 earnings call provided detailed insights into the company's financial performance and operational progress [N2].
Overview

MYOMO, INC. is a medical device company listed on the NYSE American exchange under the ticker MYO. The company focuses on developing and commercializing medical and rehabilitation devices. Its board of directors comprises six members with extensive experience in healthcare, medical devices, and finance. The company has reported consistent revenue growth in 2026, reaching a record $12.3 million in Q3, while continuing to operate at a net loss. MYOMO maintains a solid liquidity position with nearly $11.1 million in cash and equivalents and a current ratio of 1.92 as of September 30, 2026.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. MYOMO, INC. reported a net loss of $4.23 million for Q3 2026 with EPS of -$0.10. The company held $11.1 million in cash and equivalents as of September 30, 2026, with a current ratio of 1.92. MYOMO reported record Q3 2026 revenue of $12.3 million, reflecting ongoing revenue growth despite quarterly losses [S2][N1][N3].

Scenarios for MYO

Bull case model:

MYOMO has demonstrated record revenue growth in recent quarters, including $12.3 million in Q3 2026, indicating increasing market acceptance of its products. The experienced management team and board with backgrounds in medical devices and healthcare provide strategic leadership. The company's liquidity position supports ongoing operations and potential investments in growth initiatives.

Bear case model:

Despite revenue growth, MYOMO continues to report net losses, reflecting ongoing challenges in achieving profitability. The medical device industry is highly regulated and competitive, which may impact the company's ability to scale and sustain growth. Liquidity, while adequate, requires careful management to support continued operations and development efforts.

Moat:

MYOMO's moat is supported by its specialized focus on medical and rehabilitation devices, leveraging experienced leadership and board members with deep industry knowledge and successful track records in medical device commercialization. The company's ability to innovate and secure regulatory approvals, as well as its growing revenue base, contribute to its competitive positioning in a regulated healthcare market.

Risks overview
Risks summary
The primary risks for MYOMO include ongoing net losses impacting financial sustainability, regulatory and competitive challenges in the medical device sector, and the need to maintain sufficient liquidity to support operations.
Risks details:

• Continued Net Losses: MYOMO has reported net losses in recent quarters, which may impact its ability to invest in growth and sustain operations without additional financing.
• Regulatory and Market Risks: Operating in the medical device industry involves regulatory approvals and compliance risks, as well as competition from established players.
• Liquidity Risk: While current liquidity ratios are healthy, ongoing losses necessitate prudent cash management to maintain operational stability.

FINAL FORECAST FOR MYO

Final take one line
MYOMO exhibits strong business model visibility with detailed financial disclosures and consistent revenue growth amid ongoing net losses.
Final take 12 to 24 month view

Business trends: MYOMO shows consistent revenue growth with record quarterly revenues in 2026, reflecting market traction in medical devices.
Execution milestones: The company maintains solid liquidity and governance structures, with detailed quarterly reporting and active board oversight.
Key risks: Continued net losses, regulatory challenges, and the need to sustain liquidity pose ongoing operational risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • MYOMO, INC. is a publicly traded company on the NYSE American exchange under the ticker MYO [S1].
  • As of March 2, 2026, MYOMO had 38,511,715 shares of common stock outstanding [S1].
  • The company operates in the medical device industry, with a focus on medical and rehabilitation devices, as inferred from board members' backgrounds and company descriptions [S1].
  • MYOMO's board of directors consists of six members serving staggered three-year terms, with detailed biographies and qualifications provided in the 10-K/A filing dated April 29, 2026 [S1].
  • Key executives include Paul R. Gudonis as President, CEO, and Chairman of the Board [S1].
  • The company reported a net loss of $4,232,759 for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.10 per share [S2].
  • Cash and cash equivalents were $11,099,159 as of September 30, 2026, with short-term investments of $847,027, current assets of $23,499,115, and current liabilities of $12,270,129, resulting in a current ratio of 1.92 and a cash ratio of 0.97 [S2].
  • MYOMO reported record third quarter 2026 revenue of $12.3 million [N1].
  • The company has consistently reported quarterly losses but has shown revenue growth, as indicated by multiple quarterly earnings reports in 2026 [N3][N6][N1].
  • Recent news includes detailed earnings call transcripts and reports highlighting revenue achievements and loss figures for Q3 2026 [N2][N3].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
  • N2
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-29 | 10-K/A
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Myomo, Inc. Reports Record Third Quarter 2026 Revenue of $12.3 Million | https://www.nasdaq.com/articles/myomo-inc-reports-record-third-quarter-2026-revenue-123-million
  • N2 | 2026-11-10 | www.nasdaq.com | Myomo (MYO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/myomo-myo-q3-2026-earnings-call-transcript
  • N3 | 2026-11-09 | www.nasdaq.com | Myomo, Inc. (MYO) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/myomo-inc-myo-reports-q3-loss-beats-revenue-estimates
  • N4 | 2026-11-04 | www.nasdaq.com | Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates | https://www.nasdaq.com/articles/bio-rad-laboratories-bio-q3-earnings-top-estimates
  • N5 | 2026-08-07 | www.nasdaq.com | Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66% | https://www.nasdaq.com/articles/top-biotech-gainers-celz-soars-patent-news-brve-debuts-strong-iova-revenue-climbs-66
  • N6 | 2026-08-06 | www.nasdaq.com | Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/myomo-inc-myo-reports-q2-loss-tops-revenue-estimates
  • N7 | 2026-06-16 | www.nasdaq.com | Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-rgnt-withdraws-f-1-filing-fda-clears-cuprs-maggot-therapy-myo-watch
  • N8 | 2026-06-11 | www.nasdaq.com | Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-pbls-soars-over-50-clov-rallies-legal-win-rnaz-tmci-watch
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine